The therapeutic area of respiratory diseases includes diseases such as asthma, chronic obstructive pulmonary disease (COPD) or idiopathic pulmonary fibrosis (IPF). In this area, the G-BA has assessed xx medicinal products in xx procedures. The G-BA has found a major additional benefit for xx% and a considerable additional benefit for XX% of the subpopulations weighted according to patient shares in the respective resolution and in relation to the comparative therapy. The G-BA has identified a minor additional benefit for XX% and a non-quantifiable additional benefit for another XX%. No additional benefit was shown for XX% of the subpopulations and less benefit has been identified for a further xx% in relation to the comparative therapy. According to resolutions by the G-BA, xx% of the maximum of the xx million patients treatable with the evaluated medicinal products do not benefit from these medicinal products.